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ABSTRACT
Type 2 diabetes management can be improved
by the use of second-generation basal insulin
analogues as the first choice on commencement
of insulin, in this instance focussing on insulin
glargine 300 U/mL (Gla-300). The clinical
application of the use of Gla-300 include
advantages such as less intra- and interpatient
variability in glucose control resulting in rather
less hypoglycaemia, longer duration of action
and greater flexibility in the timing of admin-
istration thus suiting a wide range of patient
presentations.
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WHEN SHOULD I CONSIDER
INITIATING INSULIN?
As the worldwide prevalence of type 2 diabetes
increases (8.8% of the adult population) [1],
general practice has become the principal point
of care for the majority of these patients. Type 2
diabetes is a progressive disease associated with
multiple long-term complications [2], mostly
directly related to glycaemic control as mea-
sured by glycated haemoglobin A1c (HbA1c).
While the recent advent of newer therapies has
resulted in wider choice of treatments, insulin
remains the most effective way of lowering
blood glucose. In most clinical scenarios it is
introduced when other therapies are unable to
effectively reduce glucose levels to achieve
individualised HbA1c targets. However, there is
evidence that there still exists considerable
clinical inertia around introducing insulin.
Studies in Australia and internationally have
shown that insulin was often initiated after
HbA1c levels had remained between 8% and
9.3% for an extended period of time [3–5],
thereby increasing the risk of diabetes compli-
cations. Barriers that underlie this include
practitioner and patient fear of hypoglycaemia
and the complexity of initiation [6]. As general
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practice is the main point of care for these
patients, it is essential that healthcare providers
become familiar with the use of insulin and are
comfortable with its initiation. The newer sec-
ond-generation insulin analogues provide an
excellent option with a simple initiation regi-
men and a reduced risk of hypoglycaemia.
Insulin initiation may be useful in the fol-
lowing clinical scenarios:
1. Metabolic decompensation—hyperglycaemia
with polyuria, polydipsia, weight loss.
2. Maximally tolerated non-insulin agents
without achievement of glycaemic targets.
When insulin therapy is initiated and titra-
ted, it is important to make the correct choice to
minimise impact on patients. Choosing an
insulin that promotes simpler regimens, less
hypoglycaemia and prolonged daily activity
with less variability will allow flexibility for
modern lifestyles and dietary patterns. Newer
second-generation basal insulin analogues with
changes in pharmacodynamics can assist the
clinicians to support glycaemic management
focussing on patient needs.
To address these issues, the authors have
reviewed the evidence that second-generation
insulin analogue options can assist in improv-
ing outcomes supported by clinical guidelines.
COMPLIANCE WITH ETHICS
GUIDELINES
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.




Second-generation basal insulin analogues
insulin glargine 300 U/mL (Toujeo) and insu-
lin degludec (Tresiba) have been developed to
address clinical needs for a stable pre-
dictable basal insulin response beyond 24 h.
These insulin analogues are characterised by
different pharmacokinetic and pharmacody-
namic properties compared to insulin glargine
100 U/mL (Gla-100), a first-generation basal
insulin analogue commonly used in type 2
diabetes, and insulin detemir [7–9].
Second-generation basal insulins have a
comparatively longer duration of action
([24 h), less glycaemic fluctuation (more even
24 h distribution) and less intrapatient and
interpatient variability [10]. These pharmaco-
logical differences have important implications
for practice.
Supportive Clinical Trial Evidence
A comprehensive collection of clinical trials
comparing Gla-300 to current insulins, oral
hypoglycaemic agents and in a variety of pop-
ulations has been done [11–14] (EDITION
studies). These are multinational trials with a
range of patient populations. The ‘average’
patient was aged 57–60 years, 52–57% being
male with an HbA1c of 8.1–8.6%.
EDITION 1, 2 and 3 demonstrated lower
rates of hypoglycaemic events and particularly
nocturnal hypoglycaemia, positively comparing
Gla-300 to Gla-100 [12, 14]. EDITION 4
demonstrated comparable HbA1c levels
between the two insulins but the eventual
insulin Gla-300 dose was 0.62 U/kg/day com-
pared to 0.53 U/kg/day for Gla-100 [13].
An independent meta-analysis comparing
the EDITION and the BEGIN programmes
involving degludec (IDeg) [15] suggested that,
despite reductions in fasting plasma glucose
(FPG), IDeg was associated with less improve-
ment in HbA1c versus Gla-100 with a hypogly-
caemia benefit only evident at night. Gla-300
showed similar HbA1c reduction to Gla-100
with lower risk of hypoglycaemia both at night
and any time of the day.
Similarly, in a review of randomized con-
trolled trials (RCTs) with Gla-300 and IDeg in
patients with both type 1 and 2 diabetes [16],
the study showed that a large number of
patients succeeded in meeting HbA1c targets
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but also had less hypoglycaemic events with
both insulins versus first-generation insulin
glargine 100 U/mL.
Clinical Implications
Second-generation basal insulin analogues such
as Gla-300 and IDeg are at least as efficacious as
first-generation basal insulin analogues in gly-
caemic control but have lower risk of hypogly-
caemia (including nocturnal hypoglycaemia).
Because of the longer insulin action beyond
24 h, they are also very suitable for patients who
have irregular meal patterns, shift workers, fre-
quent travellers travelling across multiple time
zones and the forgetful patient.
UTILISING SECOND-GENERATION
INSULIN GLARGINE 300U/ML
INSULIN IN CLINICAL PRACTICE
Case Vignette 1: Commencing Insulin
and Titrating
John is a 58-year-old male non-smoker with a
body mass index (BMI) of 32 and diagnosed
with type 2 diabetes for 10 years. He is
employed at a refinery and does night shifts
every 3 weeks.
He has evidence of early peripheral neu-
ropathy and an estimated glomerular filtration
rate (eGFR) of 70 mL/min/1.73 m2 without
microalbuminuria, and no other microvascular
or macrovascular complications. Despite good
adherence to diet and exercise programs and
treatment with maximum tolerated doses of
metformin, gliclazide and sitagliptin, his HbA1c
has been consistently increasing over the past
9 months and is now 77 mmol/mol (9.2%).
Case Comment
Adequate glycaemic control is important to
prevent the onset of further microvascular
complications in a person who needs to live a
healthy life with many years ahead living with
diabetes. Thus, his individualised target HbA1c
is B 53 mmol/mol (7%) if possible, without
raising risks of hypoglycaemia. When consid-
ering the available therapies, to achieve target
HbA1c without added oral tablet burden, and
efficacy, insulin remains the glycaemic lowering
therapy that is flexible, and efficacious to assist
John in achieving his target. He would be an
ideal candidate for a second-generation ana-
logue such as insulin glargine 300 U/mL owing
to the longer duration of action and because it
can be taken at any time each day to suit his
shift work. European and American Guidelines
suggest that additional oral medication would
not be a usual choice because of the level of his
hyperglycaemia [17]. Initiating second-genera-
tion basal insulin analogues with his existing
oral glucose-lowering therapies provides an
opportunity to reduce delays in achieving
effective glycaemic control (i.e. clinical inertia)
[18, 19]. The Bright study revealed that using
Gla-300 could achieve adequate glycaemic
control compared to IDeg with lower rates of
hypoglycaemia [18]. Adding a Gla-300 to exist-
ing oral regimes may also offset the need for
escalating doses of insulin. Alternatives could
be a long-acting glucagon-like peptide 1 (GLP-1)
receptor agonists but rationalisation of existing
therapies would need to be hastened (ceasing
the dipeptidyl peptidase 4 inhibitor [DPP4i] at
initiation), potentially destabilising glycaemic
control at this vital stage of upgrading gly-
caemic management. Also, GLP-1 agents lack
the greater flexibility to titrate doses to gly-
caemic effect compared to insulin. As John has
no established cardiac disease, the imperative to
use agents that have been shown to benefit
patients with established cardiovascular disease,
such as a sodium/glucose cotransporter 2 inhi-
bitor (SGLT2i) and liraglutide or dulaglutide
(GLP-1 receptor agonists), may not be a priority.
Initiation of Basal Insulin
In insulin-naive patients, the recommendation
is to commence a single daily insulin dose of
Gla-300, commencing with 0.2 units/kg = 18
units] The titration goal is to achieve a morning
Diabetes Ther (2019) 10:1987–1994 1989
fasting glucose between 4 and 7 mmol/L [20].
John was instructed in self-monitoring of his
glucose plus hypoglycaemia management and
asked to increase his dose as per Fig. 1, until he
achieves his target fasting glucose without
symptomatic or measurable hypoglycaemia.
Once John is close to achieving his fasting
glucose goal and HbA1c, consideration should
be given to reviewing existing oral therapies (see
Fig. 3). His sulphonylurea (gliclazide) could be
ceased to reduce the risk of hypoglycaemia but
this must be matched by insulin dose titration
to prevent further hyperglycaemia. If a
replacement treatment is required considera-
tion could be given to adding an agent to his
metformin such as an SGLT2i. Alternatively,
consideration could be given to gradually ceas-
ing both his DPP4i (sitagliptin) and sulphony-
lurea (gliclazide) and introducing a GLP-1
receptor agonist such as short-acting exenatide
to address his postprandial hyperglycaemia
which may offer similar advantages but at the
inconvenience of additional daily injections
[21].
Case Vignette 2: Switching Between
Insulin Regimes
Mary is a 64-year-old non-smoker who has had
type 2 diabetes for 16 years. She is on a pre-mix
(NovoMix 30) insulin at 40 units with her
main meal and 48 units with her evening meal,
as well as metformin 2 g/day, and empagliflozin
25 mg/day. Since commencing insulin she has
gained about 6% of her body weight and now
weighs 102 kg. She has atherosclerotic cardio-
vascular disease (ASCVD), chronic kidney dis-
ease (CKD) stage 3a (eGFR = 52), peripheral
neuropathy and moderate non-proliferative
diabetic retinopathy. She is troubled by fre-
quent episodes of hypoglycaemia measured by
flash glucose monitoring, especially overnight,
and is becoming concerned as she lives alone.
Her HbA1c (66 mmol/mol; 8.2%) is still not at
her agreed target of 58 mmol/mol (7.5%).
Case Comment
In patients who are on insulin therapy and
experiencing hypoglycaemic episodes, switch-
ing to a second-generation basal insulin ana-
logue is an option. Continuous glucose
monitoring (CGM) can be used to detect hidden
hypoglycaemic episodes [22, 23]. Switching to a
second-generation basal insulin analogue is a
logical choice e.g. for the elderly, those living
alone, those with inadequate glucose control
requiring intensification or in patients having
difficulties maintaining a strict 24-h dosing
schedule.
Hypoglycaemia is a major risk factor for
Mary and the risk could be considerably
reduced by switching her to a second-gener-
Fig. 1 Commencing insulin glargine 300 U/mL (Toujeo)
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ation basal insulin analogue plus a short-act-
ing insulin if required (basal plus) or basal
insulin with a GLP-1 receptor agonist. This
reflects a flatter 24-h glycaemic lowering
effect of the newer-generation insulin ana-
logues [7–9].
When commencing glargine U300, the
starting dose would be her total daily insulin
less 30% [(40 units ? 48 units = 88 units) -
30% = 58 units] (see Fig. 2). This could be
introduced as a single morning or evening dose.
Her Gla-300 will be titrated against her fasting
blood glucose level (BGL).
Once her morning fasting blood glucose is
near 6 mmol/L, and there is no evidence of
hypoglycaemia, we can focus on closely moni-
toring her postprandial blood glucose. If there is
significant postprandial BGL excursions (see
Fig. 3), consideration could be given to the
introduction of a GLP-1 receptor agonist with
proven cardiovascular benefits, to assist with
controlling the postprandial glucose and help
her reduce weight without a significant
increased risk of hypoglycaemia or introducing
short-acting insulin, initially to those meals
showing the greatest postprandial BGL excur-
sions (basal plus) where a GLP-1 receptor ago-
nist may not be efficacious enough to control
significant postprandial hyperglycaemia (see
Fig. 4).
SUMMARY PRACTICE POINTS
See Figs. 2, 3 and 4.
Fig. 2 Switching to insulin glargine 300 U/mL (Toujeo)
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